Ultragenyx Pharmaceutical Inc. (BMV:RARE)
Mexico · Delayed Price · Currency is MXN | Market Cap | 24.62B -51.4% |
| Revenue (ttm) | 12.53B +17.5% |
| Net Income | -10.24B |
| EPS | -101.83 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133 |
| Open | 255.00 |
| Previous Close | 450.00 |
| Day's Range | 252.00 - 255.00 |
| 52-Week Range | 252.00 - 460.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2025, Ultragenyx Pharmaceutical's revenue was $673.00 million, an increase of 20.18% compared to the previous year's $560.00 million. Losses were -$575.00 million, 1.05% more than in 2024.
Financial numbers in USD Financial StatementsNews
Ultragenyx price target raised to $35 from $32 at Barclays
Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of Fayuvi. The Angelman miss hurt…
Ultragenyx price target raised to $20 from $18 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Ultragenyx (RARE) to $20 from $18 and keeps an Equal Weight rating on the shares. Fayuvi’s standard full approval in Sanfilippo Syndrome…
Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111
Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI, also known as UX111, a gene therapy for the treatment of ...
Ultragenyx price target raised to $39 from $37 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $39 from $37 and keeps a Buy rating on the shares. The firm updated its model following…
Ultragenyx price target raised to $39 from $33 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Ultragenyx (RARE) to $39 from $33 and keeps an Overweight rating on the shares. The approval of FAYUVI for Sanfilippo syndrome type…
Ultragenyx price target raised to $32 from $31 at Citi
Citi raised the firm’s price target on Ultragenyx (RARE) to $32 from $31 and keeps a Buy rating on the shares. The firm views the FDA approval of Fayuvi with…
Ultragenyx Pharmaceutical Transcript: FDA announcement
FDA granted full approval to FAYUVI, the first gene therapy for Sanfilippo syndrome type A, based on robust long-term data. The therapy will be available in the U.S. within 30-60 days at a $3.95M price, with plans for global expansion and ongoing patient monitoring.
Ultragenyx Pharmaceutical Press release: FDA announcement
Ultragenyx Pharmaceutical issued a press release on September 17, 2026, disclosing material business information to investors.
Ultragenyx confirms FDA approval of Fayuvi
Ultragenyx (RARE) announced that the U.S. FDA granted standard full approval of Fayuvi, also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis type IIIA. Fayuvi is the...
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo synd...
US FDA approves Ultragenyx's gene therapy for rare disorder
The U.S Food and Drug Administration said on Thursday it has approved Ultragenyx's gene therapy for the treatment of a rare, fatal disease.
Ultragenyx treatment of GNE myopathy granted orphan designation
Ultragenyx (RARE) Pharmaceutical was granted FDA orphan designation for a treatment of GNE myopathy, according to a post to the agency’s website.
Ultragenyx price target lowered to $32 from $43 at Barclays
Barclays analyst Eliana Merle lowered the firm’s price target on Ultragenyx (RARE) to $32 from $43 and keeps an Overweight rating on the shares. The firm removed Angelman syndrome from…
Ultragenyx downgraded at Morgan Stanley after Angelman study fails
As previously reported, Morgan Stanley downgraded Ultragenyx (RARE) to Equal Weight from Overweight with a price target of $18, down from $74, after the company announced that its Phase 3…
Ultragenyx downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Maxwell Skor downgraded Ultragenyx (RARE) to Equal Weight from Overweight with a price target of $18, down from $74.
Ultragenyx falls -44.0%
Ultragenyx (RARE) is down -44.0%, or -$11.67 to $14.86.
Ultragenyx falls -44.6%
Ultragenyx (RARE) is down -44.6%, or -$11.83 to $14.70.
Ultragenyx downgraded to Neutral from Buy at BofA
BofA downgraded Ultragenyx (RARE) to Neutral from Buy with a price target of $20, down from $48, following the announcement that the Phase 3 ASPIRE study of apazunersen in Angelman…
Why Is Ultragenyx Pharmaceutical Stock (RARE) Down Today?
Ultragenyx Pharmaceutical stock fell over 46% on Thursday following a clinical trial update.
Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet.
Ultragenyx Pharmaceuticals looks to cut costs following the trial failure, while attention remains squared on its burgeoning commercial business.
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial
Shares of Ultragenyx Pharmaceutical plunged more than 40% in premarket on Thursday after its neurodevelopmental disorder treatment failed a closely watched late-stage trial, dealing a major blow to o...
Ultragenyx's rare disease drug fails in late-stage trial; shares plunge
Ultragenyx Pharmaceutical said on Wednesday its experimental drug for a rare genetic neurodevelopmental disorder did not meet the main goal in a late-stage trial, sending its shares down 40% in af...
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI)
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
At Week 96, participants across treatment and crossover groups experienced mean reduction in daily cornstarch intake of 61% while maintaining glycemic control, with most participants achieving reducti...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...